<DOC>
	<DOCNO>NCT03012646</DOCNO>
	<brief_summary>This multicenter , single-arm trial evaluate safety efficacy inhale treprostinil subject pre-capillary pulmonary hypertension ( PH ) associate Chronic Obstructive Pulmonary Disease ( COPD ) .</brief_summary>
	<brief_title>Safety Tolerability Inhaled Treprostinil Adult PH Due COPD</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>1 . Diagnosis WHO Group 3 PH associate COPD 2 . Subjects require right heart catheterization ( RHC ) within one year prior first dose study drug follow parameter : 1 . Pulmonary vascular resistance ( PVR ) ≥ 4 Wood Units ( WU ) 2 . A leave ventricular end diastolic pressure ( LVEDP ) pulmonary capillary wedge pressure ( PCWP ) ≤ 12 mmHg PVR ≥ 4 WU &lt; 6.25 WU ≤ 15 mmHg PVR ≥ 6.25 WU 3 . A mean pulmonary arterial pressure ( mPAP ) ≥ 30 mmHg 3 . Clinical Diagnosis COPD make use accepted Global Initiative Chronic Obstructive Lung Disease ( GOLD ) diagnostic criterion , include Baseline spirometry follow documented parameter : 1 . FEV1 &lt; 65 % predict , 2 . FEV1/ FVC &lt; 70 4 . Baseline 6MWD ≥ 100 meter Exclusion criterion : 1 . The subject diagnosis pulmonary arterial hypertension ( PAH ) PH reason COPD outline inclusion criterion 3 . This would include , limited , concomitant presence thromboembolic disease ( acute chronic ) , untreated inadequately treated obstructive sleep apnea , connective tissue disease ( include limit systemic sclerosis/scleroderma , systemic lupus erythematosus ) , sarcoidosis , interstitial lung disease , human immunodeficiency virus1 infection , condition WHO Group 1 , 2 , 4 , 5 classification . 2 . The subject receive Food Drug Administration ( FDA ) approve medication treatment PAH ( ie , prostacyclin , prostacyclin receptor agonist , endothelin receptor antagonist [ ERA ] , phosphodiesterase type 5 inhibitor [ PDE5I ] , soluble guanylate cyclase [ sGC ] stimulator ) within 60 day first dose study drug , except acute vasoreactivity test . 3 . The subject evidence clinically significant leftsided heart disease define follow criterion per recent assessment : 1 . Left ventricular end diastolic pressure ( LVEDP ) pulmonary capillary wedge pressure ( PCWP ) &gt; 15 mmHg ( &gt; 12 mmHg pulmonary vascular resistance [ PVR ] ≥4 &lt; 6.25 WU ) 2 . Left ventricular ejection fraction &lt; 40 % assess either angiography echocardiography .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Treprostinil</keyword>
	<keyword>PH</keyword>
	<keyword>COPD</keyword>
	<keyword>6 Minute Walk Test</keyword>
</DOC>